Genmab A GMAB
NASDAQ GMAB
$40.00 +0.43 (+1.09%)
At close: Oct 22, 2026 · 4:00 PM EDT

Genmab A (GMAB) Gross Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported Gross Margin of 92.73% for the quarter ended Jun 30, 2026, down 0.02 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) Gross Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's Gross Margin came in at 93.63%; for the year ended Dec 31, 2025, it came in at 93.60%, down 1.82 percentage points from the prior year.

  • By year, Gross Margin came in at 95.42% in the year ended Dec 31, 2024 (+31.26 pp) and 64.16% in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn 68.12%
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn 74.74%
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn 73.54%
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn 78.02%
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn 83.60%
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn 72.04%
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn 79.76%
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn 72.78%
10 Genmab A 2.58 Bn -2.80 Bn 1.07 Bn 92.73%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 92.73%
Mar 31, 2026 92.75%
Sep 30, 2025 94.32%
Jun 30, 2025 93.84%
Mar 31, 2025 94.13%
Sep 30, 2024 95.10%
Jun 30, 2024 96.41%
Mar 31, 2024 95.52%
Sep 30, 2023 98.32%
API Access

Genmab A Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY